

# Lisa Ng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9130549/publications.pdf>

Version: 2024-02-01

161  
papers

13,357  
citations

36303

51  
h-index

26613

107  
g-index

175  
all docs

175  
docs citations

175  
times ranked

23277  
citing authors

#	ARTICLE	IF	CITATIONS
1	The trinity of COVID-19: immunity, inflammation and intervention. <i>Nature Reviews Immunology</i> , 2020, 20, 363-374.	22.7	3,347
2	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	9.6	444
3	Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. <i>Lancet, The</i> , 2003, 361, 1779-1785.	13.7	423
4	Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. <i>Lancet, The</i> , 2020, 396, 603-611.	13.7	394
5	Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. <i>Nature Communications</i> , 2020, 11, 2806.	12.8	362
6	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. <i>Lancet Microbe, The</i> , 2021, 2, e240-e249.	7.3	322
7	Persistent Arthralgia Induced by Chikungunya Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Infectious Diseases</i> , 2011, 203, 149-157.	4.0	305
8	Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. <i>Lancet Infectious Diseases, The</i> , 2017, 17, e107-e117.	9.1	302
9	IL-1 $\beta$ , IL-6, and RANTES as Biomarkers of Chikungunya Severity. <i>PLoS ONE</i> , 2009, 4, e4261.	2.5	249
10	Active Infection of Human Blood Monocytes by Chikungunya Virus Triggers an Innate Immune Response. <i>Journal of Immunology</i> , 2010, 184, 5903-5913.	0.8	237
11	Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. <i>Frontiers in Immunology</i> , 2020, 11, 879.	4.8	218
12	A Pathogenic Role for CD4+ T Cells during Chikungunya Virus Infection in Mice. <i>Journal of Immunology</i> , 2013, 190, 259-269.	0.8	196
13	Catching bird flu in a droplet. <i>Nature Medicine</i> , 2007, 13, 1259-1263.	30.7	195
14	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. <i>Cell</i> , 2020, 181, 1194-1199.	28.9	185
15	Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. <i>EMBO Molecular Medicine</i> , 2012, 4, 330-343.	6.9	177
16	Viperin restricts chikungunya virus replication and pathology. <i>Journal of Clinical Investigation</i> , 2012, 122, 4447-4460.	8.2	163
17	Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection. <i>Journal of Infectious Diseases</i> , 2012, 205, 1147-1154.	4.0	156
18	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. <i>Clinical Infectious Diseases</i> , 2021, 73, e2932-e2942.	5.8	143

#	ARTICLE	IF	CITATIONS
19	Cleavage of the SARS Coronavirus Spike Glycoprotein by Airway Proteases Enhances Virus Entry into Human Bronchial Epithelial Cells In Vitro. PLoS ONE, 2009, 4, e7870.	2.5	142
20	Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nature Communications, 2020, 11, 5243.	12.8	138
21	An Essential Role of Antibodies in the Control of Chikungunya Virus Infection. Journal of Immunology, 2013, 190, 6295-6302.	0.8	135
22	Zika Virus Infects Human Fetal Brain Microglia and Induces Inflammation. Clinical Infectious Diseases, 2017, 64, 914-920.	5.8	133
23	The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. Journal of Virology, 2016, 90, 9743-9757.	3.4	127
24	Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. Viruses, 2018, 10, 268.	3.3	126
25	Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development. Journal of Virology, 2012, 86, 13005-13015.	3.4	125
26	Re-emergence of Chikungunya virus in South-east Asia: virological evidence from Sri Lanka and Singapore. Journal of General Virology, 2010, 91, 1067-1076.	2.9	124
27	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	6.1	120
28	Cerebral malaria. Virulence, 2012, 3, 193-201.	4.4	118
29	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 2021, 10, .	6.0	113
30	Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Research, 2017, 144, 223-246.	4.1	104
31	A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection. Journal of Infectious Diseases, 2015, 211, 1925-1935.	4.0	95
32	Caribbean and La R�union Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology. Journal of Virology, 2015, 89, 7955-7969.	3.4	95
33	Chikungunya: a bending reality. Microbes and Infection, 2009, 11, 1165-1176.	1.9	93
34	Identification of a Novel Cleavage Activity of the First Papain-Like Proteinase Domain Encoded by Open Reading Frame 1a of the Coronavirus Avian Infectious Bronchitis Virus and Characterization of the Cleavage Products. Journal of Virology, 2000, 74, 1674-1685.	3.4	91
35	COVID-19 vaccines and kidney disease. Nature Reviews Nephrology, 2021, 17, 291-293.	9.6	91
36	Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants. PLoS Pathogens, 2011, 7, e1002390.	4.7	88

#	ARTICLE	IF	CITATIONS
37	Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virus-Infected Patients in Brazil. <i>Journal of Infectious Diseases</i> , 2017, 216, 172-181.	4.0	82
38	Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency. <i>Journal of Immunology</i> , 2011, 186, 3258-3264.	0.8	81
39	Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. <i>EMBO Molecular Medicine</i> , 2015, 7, 24-41.	6.9	81
40	A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. <i>BMC Infectious Diseases</i> , 2004, 4, 34.	2.9	77
41	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. <i>Nature Microbiology</i> , 2017, 2, 1435-1445.	13.3	77
42	Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab156.	0.9	77
43	Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. <i>JCI Insight</i> , 2017, 2, .	5.0	74
44	Immuno-biology of Chikungunya and implications for disease intervention. <i>Microbes and Infection</i> , 2009, 11, 1186-1196.	1.9	73
45	Epitope-Functionalized Gold Nanoparticles for Rapid and Selective Detection of SARS-CoV-2 IgG Antibodies. <i>ACS Nano</i> , 2021, 15, 12286-12297.	14.6	73
46	SVM-based prediction of linear B-cell epitopes using Bayes Feature Extraction. <i>BMC Genomics</i> , 2010, 11, S21.	2.8	68
47	Prime-Boost Immunization Strategies against Chikungunya Virus. <i>Journal of Virology</i> , 2014, 88, 13333-13343.	3.4	63
48	Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3445.	3.0	60
49	Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease. <i>Frontiers in Microbiology</i> , 2017, 8, 2249.	3.5	60
50	Chikungunya Virus Pathogenesis and Immunity. <i>Vector-Borne and Zoonotic Diseases</i> , 2015, 15, 241-249.	1.5	59
51	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	59
52	Therapeutics and Vaccines Against Chikungunya Virus. <i>Vector-Borne and Zoonotic Diseases</i> , 2015, 15, 250-257.	1.5	58
53	Fingolimod treatment abrogates chikungunya virus-induced arthralgia. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	57
54	Cellular and molecular mechanisms of chikungunya pathogenesis. <i>Antiviral Research</i> , 2015, 120, 165-174.	4.1	52

#	ARTICLE	IF	CITATIONS
55	Detection of Severe Acute Respiratory Syndrome Coronavirus in Blood of Infected Patients. <i>Journal of Clinical Microbiology</i> , 2004, 42, 347-350.	3.9	51
56	Severity of Plasma Leakage Is Associated With High Levels of Interferon $\gamma$ -Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, 42-51.	4.0	51
57	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020, 12, 1164.	3.3	51
58	Expanding Regulatory T Cells Alleviates Chikungunya Virus-Induced Pathology in Mice. <i>Journal of Virology</i> , 2015, 89, 7893-7904.	3.4	49
59	Host Heterogeneous Ribonucleoprotein K (hnRNP K) as a Potential Target to Suppress Hepatitis B Virus Replication. <i>PLoS Medicine</i> , 2005, 2, e163.	8.4	47
60	Nonstructural Proteins of Alphavirus—Potential Targets for Drug Development. <i>Viruses</i> , 2018, 10, 71.	3.3	47
61	Unique Epitopes Recognized by Antibodies Induced in Chikungunya Virus-Infected Non-Human Primates: Implications for the Study of Immunopathology and Vaccine Development. <i>PLoS ONE</i> , 2014, 9, e95647.	2.5	44
62	Persistence of Zika virus in conjunctival fluid of convalescence patients. <i>Scientific Reports</i> , 2017, 7, 11194.	3.3	43
63	Further Characterization of the Coronavirus Infectious Bronchitis Virus 3C-like Proteinase and Determination of a New Cleavage Site. <i>Virology</i> , 2000, 272, 27-39.	2.4	42
64	Macrophage Migration Inhibitory Factor Receptor CD74 Mediates Alphavirus-Induced Arthritis and Myositis in Murine Models of Alphavirus Infection. <i>Arthritis and Rheumatism</i> , 2013, 65, 2724-2736.	6.7	40
65	Trisubstituted Thieno[3,2- <i>b</i> ]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9196-9213.	6.4	40
66	Longitudinal Study of Cellular and Systemic Cytokine Signatures to Define the Dynamics of a Balanced Immune Environment During Disease Manifestation in Zika Virus-Infected Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 814-824.	4.0	40
67	Chikungunya virus nsP4 RNA-dependent RNA polymerase core domain displays detergent-sensitive primer extension and terminal adenylyltransferase activities. <i>Antiviral Research</i> , 2017, 143, 38-47.	4.1	39
68	Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. <i>Scientific Reports</i> , 2018, 8, 1860.	3.3	38
69	Identification of a 24-kDa Polypeptide Processed from the Coronavirus Infectious Bronchitis Virus 1a Polyprotein by the 3C-like Proteinase and Determination of Its Cleavage Sites. <i>Virology</i> , 1998, 243, 388-395.	2.4	37
70	SARS Transmission Pattern in Singapore Reassessed by Viral Sequence Variation Analysis. <i>PLoS Medicine</i> , 2005, 2, e43.	8.4	37
71	Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology. <i>Immunologic Research</i> , 2012, 53, 136-147.	2.9	37
72	Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. <i>Virology Journal</i> , 2013, 10, 169.	3.4	37

#	ARTICLE	IF	CITATIONS
73	Therapeutic modulation of the bile acid pool by <i>Cyp8b1</i> knockdown protects against nonalcoholic fatty liver disease in mice. <i>FASEB Journal</i> , 2018, 32, 3792-3802.	0.5	37
74	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100193.	6.5	37
75	Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e14045.	6.9	36
76	An Integrated Lab-on-Chip for Rapid Identification and Simultaneous Differentiation of Tropical Pathogens. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3043.	3.0	33
77	Immunopathology of Chikungunya Virus Infection: Lessons Learned from Patients and Animal Models. <i>Annual Review of Virology</i> , 2017, 4, 413-427.	6.7	33
78	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa375.	0.9	33
79	Specific detection of H5N1 avian influenza A virus in field specimens by a one-step RT-PCR assay. <i>BMC Infectious Diseases</i> , 2006, 6, 40.	2.9	32
80	Role of Pentraxin 3 in Shaping Arthritogenic Alphaviral Disease: From Enhanced Viral Replication to Immunomodulation. <i>PLoS Pathogens</i> , 2015, 11, e1004649.	4.7	32
81	Zika Virus Infection Preferentially Counterbalances Human Peripheral Monocyte and/or NK Cell Activity. <i>MSphere</i> , 2018, 3, .	2.9	32
82	Zika Virus and the Eye. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 654-659.	1.8	32
83	Novel differential linear B cell epitopes to identify Zika and dengue virus infections in patients. <i>Clinical and Translational Immunology</i> , 2019, 8, e1066.	3.8	32
84	Rapid detection of viral RNA by a pocket-size real-time PCR system. <i>Lab on A Chip</i> , 2010, 10, 2632.	6.0	31
85	Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. <i>Clinical and Translational Immunology</i> , 2020, 9, e1160.	3.8	31
86	<i>Viperin</i> controls chikungunya virus-specific pathogenic T cell IFN $\gamma$ Th1 stimulation in mice. <i>Life Science Alliance</i> , 2019, 2, e201900298.	2.8	31
87	Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. <i>EMBO Molecular Medicine</i> , 2022, 14, e15227.	6.9	31
88	Early clearance of Chikungunya virus in children is associated with a strong innate immune response. <i>Scientific Reports</i> , 2016, 6, 26097.	3.3	30
89	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3165-3186.	6.4	30
90	Membrane Association and Dimerization of a Cysteine-Rich, 16-Kilodalton Polypeptide Released from the C-Terminal Region of the Coronavirus Infectious Bronchitis Virus 1a Polyprotein. <i>Journal of Virology</i> , 2002, 76, 6257-6267.	3.4	27

#	ARTICLE	IF	CITATIONS
91	Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells. Nature Microbiology, 2021, 6, 991-999.	13.3	26
92	A Sensitive Method for Detecting Zika Virus Antigen in Patients's™ Whole-Blood Specimens as an Alternative Diagnostic Approach. Journal of Infectious Diseases, 2017, 216, 182-190.	4.0	25
93	Seroprevalence of antibodies against chikungunya virus in Singapore resident adult population. PLoS Neglected Tropical Diseases, 2017, 11, e0006163.	3.0	25
94	Zika virus: from an obscurity to a priority. Microbes and Infection, 2018, 20, 635-645.	1.9	25
95	Clinical features of patients with Zika and dengue virus co-infection in Singapore. Journal of Infection, 2017, 74, 611-615.	3.3	24
96	Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. Journal of Virology, 2016, 90, 1169-1177.	3.4	23
97	Plasmodium co-infection protects against chikungunya virus-induced pathologies. Nature Communications, 2018, 9, 3905.	12.8	23
98	Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate. EMBO Molecular Medicine, 2019, 11, .	6.9	23
99	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 2088-2096.	5.8	23
100	Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific, 2021, 15, 100276.	2.9	22
101	Neutrophils: Neglected Players in Viral Diseases. DNA and Cell Biology, 2013, 32, 665-675.	1.9	21
102	Clustering HLA Class I Superfamilies Using Structural Interaction Patterns. PLoS ONE, 2014, 9, e86655.	2.5	21
103	Mosquito Saliva Reshapes Alphavirus Infection and Immunopathogenesis. Journal of Virology, 2018, 92, .	3.4	21
104	Co-infection with Chikungunya virus alters trafficking of pathogenic CD8 <sup>+</sup> T cells into the brain and prevents Plasmodium-induced neuropathology. EMBO Molecular Medicine, 2018, 10, 121-138.	6.9	21
105	Chikungunya virus drug discovery: still a long way to go?. Expert Opinion on Drug Discovery, 2019, 14, 855-866.	5.0	21
106	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine, 2021, 66, 103319.	6.1	21
107	Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. Antiviral Research, 2017, 139, 79-87.	4.1	20
108	Immunological observations and transcriptomic analysis of trimester-specific full-term placentas from three Zika virus-infected women. Clinical and Translational Immunology, 2019, 8, e01082.	3.8	20

#	ARTICLE	IF	CITATIONS
109	Systematic analysis of disease-specific immunological signatures in patients with febrile illness from Saudi Arabia. <i>Clinical and Translational Immunology</i> , 2020, 9, e1163.	3.8	20
110	Chikungunya fever – Re-emergence of an old disease. <i>Microbes and Infection</i> , 2009, 11, 1163-1164.	1.9	19
111	Efficient detection of Zika virus RNA in patients' blood from the 2016 outbreak in Campinas, Brazil. <i>Scientific Reports</i> , 2018, 8, 4012.	3.3	19
112	Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2020, 9, e1159.	3.8	19
113	Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005191.	4.7	18
114	A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2973-2989.	3.0	18
115	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. <i>ACS Infectious Diseases</i> , 2018, 4, 605-619.	3.8	18
116	Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. <i>Clinical and Translational Immunology</i> , 2021, 10, e1241.	3.8	18
117	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	6.0	17
118	HLA Class I Restriction as a Possible Driving Force for Chikungunya Evolution. <i>PLoS ONE</i> , 2010, 5, e9291.	2.5	15
119	Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 382 Variant Infection. <i>Journal of Clinical Immunology</i> , 2022, 42, 214-229.	3.8	15
120	VCP/p97 Is a Proviral Host Factor for Replication of Chikungunya Virus and Other Alphaviruses. <i>Frontiers in Microbiology</i> , 2019, 10, 2236.	3.5	14
121	Host response to Chikungunya virus and perspectives for immune-based therapies. <i>Future Virology</i> , 2011, 6, 975-984.	1.8	13
122	Limitations of Current in Vivo Mouse Models for the Study of Chikungunya Virus Pathogenesis. <i>Medical Sciences (Basel, Switzerland)</i> , 2015, 3, 64-77.	2.9	12
123	Interferon regulatory factor 1 is essential for pathogenic CD8+ T cell migration and retention in the brain during experimental cerebral malaria. <i>Cellular Microbiology</i> , 2018, 20, e12819.	2.1	12
124	Role of T Cells in Chikungunya Virus Infection and Utilizing Their Potential in Anti-Viral Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 287.	4.8	12
125	Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice. <i>Scientific Reports</i> , 2016, 6, 37603.	3.3	11
126	ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 203-212.	4.0	11



#	ARTICLE	IF	CITATIONS
127	TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection. <i>Scientific Reports</i> , 2020, 10, 3810.	3.3	11
128	A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. <i>Journal of Virological Methods</i> , 2015, 222, 55-61.	2.1	10
129	Age has a role in driving host immunopathological response to alphavirus infection. <i>Immunology</i> , 2017, 152, 545-555.	4.4	10
130	The 2016 Singapore Zika virus outbreak did not cause a surge in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 197-201.	3.1	10
131	Gas6 drives Zika virus-induced neurological complications in humans and congenital syndrome in immunocompetent mice. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 260-274.	4.1	10
132	Cellular transcription modulator SMARCE1 binds to HBV core promoter containing naturally occurring deletions and represses viral replication. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 1075-1084.	3.8	9
133	<i>Arbovirus Infections.</i> , 2014, , 129-161.e3.		9
134	Pathogenic Th1 responses in CHIKV-induced inflammation and their modulation upon Plasmodium parasites co-infection. <i>Immunological Reviews</i> , 2020, 294, 80-91.	6.0	9
135	Type I interferon shapes the quantity and quality of the anti-Zika virus antibody response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1126.	3.8	8
136	Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape. <i>Microorganisms</i> , 2021, 9, 899.	3.6	8
137	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 710217.	4.8	8
138	A cell-based system for hepatitis B virus replication: significance of clinically enhanced viral replication in relation to deletions in viral core promoter. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2001.	3.0	7
139	In silico prediction of the granzyme B degradome. <i>BMC Genomics</i> , 2011, 12, S11.	2.8	7
140	Fast Tracks and Roadblocks for Zika Vaccines. <i>Vaccines</i> , 2018, 6, 77.	4.4	7
141	Viperin Poisons Viral Replication. <i>Cell Host and Microbe</i> , 2018, 24, 181-183.	11.0	7
142	Investigating the Cellular Transcriptomic Response Induced by the Makona Variant of Ebola Virus in Differentiated THP-1 Cells. <i>Viruses</i> , 2019, 11, 1023.	3.3	6
143	Understanding Molecular Pathogenesis with Chikungunya Virus Research Tools. <i>Current Topics in Microbiology and Immunology</i> , 2019, , 1.	1.1	6
144	Further Identification and Characterization of Products Processed from the Coronavirus Avian Infectious Bronchitis Virus (IBV) 1a Polyprotein by the 3C-like Proteinase. <i>Advances in Experimental Medicine and Biology</i> , 2001, 494, 291-298.	1.6	6

#	ARTICLE	IF	CITATIONS
145	The fine line between protection and pathology in neurotropic flavivirus and alphavirus infections. <i>Future Virology</i> , 2014, 9, 313-330.	1.8	5
146	Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus Infection. <i>Frontiers in Immunology</i> , 2020, 11, 894.	4.8	5
147	Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cells. <i>Life Science Alliance</i> , 2022, 5, e202101272.	2.8	5
148	Chikungunya: International Focus Issue. <i>Vector-Borne and Zoonotic Diseases</i> , 2015, 15, 221-222.	1.5	4
149	Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. <i>Scientific Reports</i> , 2018, 8, 17125.	3.3	4
150	Rapid microfluidic platform for screening and enrichment of cells secreting virus neutralizing antibodies. <i>Lab on A Chip</i> , 2022, 22, 2578-2589.	6.0	4
151	Understanding infectious agents from an in silico perspective. <i>Drug Discovery Today</i> , 2011, 16, 42-49.	6.4	3
152	Major advances against a moving target of CNS infections. <i>Nature Reviews Neurology</i> , 2015, 11, 623-624.	10.1	3
153	The Virus That Changed My World. <i>PLoS Biology</i> , 2003, 1, e66.	5.6	2
154	Further Characterisation of the Coronavirus IBV ORF 1a Products Encoded by the 3C-Like Proteinase Domain and the Flanking Regions. <i>Advances in Experimental Medicine and Biology</i> , 1998, 440, 161-171.	1.6	2
155	Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients. , 2019, 8, e1066.		1
156	A promiscuous interaction of SARS-CoV-2 with bacterial products. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 914-915.	3.3	1
157	Discrepant serological findings in SARS-CoV-2 PCR-negative hospitalized patients with fever and acute respiratory symptoms during the pandemic. <i>Journal of Medical Virology</i> , 2022, , .	5.0	1
158	Host Response and Mechanisms of Subversion of Chikungunya. , 2016, , 19-32.		0
159	Type I Interferon Shapes the Quantity and Quality of the Anti-Zika Virus Antibody Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
160	Association of SARS-CoV-2 Clades with Clinical, Inflammatory and Virologic Outcomes: An Observational Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
161	Organ-specific immune response in lethal SARS-CoV-2 infection by deep spatial phenotyping. <i>Clinical and Translational Immunology</i> , 2022, 11, .	3.8	0